First human test for new HIV vaccine strategy
NCT ID NCT06253533
Summary
This early-stage study tested the safety and immune response of a new DNA vaccine, called ICVAX, in people living with HIV who are stable on their regular medication. It involved 45 participants who received different doses of the vaccine or a placebo. The main goal was to see if the vaccine was safe and if it could stimulate the immune system to fight the virus.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shenzhen Third People's Hospital
Shenzhen, Guangdong, 518112, China
Conditions
Explore the condition pages connected to this study.